On January 27, 1964, Academician Lu Daopei, the "founder of bone marrow transplantation in China," successfully performed Asia's first and the world's fourth allogeneic bone marrow transplantation at Peking University People's Hospital. This opened the era of hematopoietic stem cell transplantation (HSCT) for treating hematological diseases in China, bringing new hope to countless hematology patients.

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

CAR-T therapy, the 4th major cancer treatment, engineers patient's T cells to target cancers. Highly effective for blood cancers like leukemia & lymphoma. Promising for solid tumors & non-cancer diseases. Faces challenges like cost & side effects, but research is advancing rapidly.